Clinical trials: Dosimetry
Metastatic Prostate Cancer
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592).
- Trial name
- CUPID (NCT04726033)
- Testing
- 64Cu-DOTA-TLX592
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Neuroendocrine Tumors
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE.
- Trial name
- NCT02743741
- Testing
- Lutetium-177 Octreotate
- Where
- 4 sites in Canada
- Volunteers
- 195 people
- Sponsor
- University Health Network, Toronto
Orofacial Pain, Tension-Type Headache
Photobiomodulation Dosimetry s in Patients With Orofacial Pain
This project aims to validate a dosimetry model for photobiomodulation treatment in patients with orofacial pain and tension-type headache symptoms. The study will involve 240 participants divided into four age groups.
- Trial name
- NCT06065969
- Testing
- Photobiomodulation
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Nove de Julho
Neuroblastoma
124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study
This is a pilot study with the primary purpose to describe organ dosimetry and acute toxicities using no carrier added and carrier added 124I-MIBG PET/CT in patients with neuroblastoma (NB).
- Trial name
- NCT01583842
- Testing
- 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added), 124I-MIBG (carrier added), Positron Emission Tomography (PET) /Computerized tomography (CT)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Miguel Pampaloni
Healthy
Use of [18F]FECNT in Positron Emission Tomography
This study will examine the use of a new radioactive tracer called [18F]FECNT in positron emission tomography (PET) scanning for measuring dopamine transporter (DAT) in the brain.
- Trial name
- NCT00083629
- Testing
- PET
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Cervical Cancer
Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer
This prospective, single-center study will evaluate the feasibility, spatial stability, and dosimetric effects of an absorbable hydrogel spacer placed between the cervix/vagina and rectum before definitive radiotherapy for…
- Trial name
- Hydrogel-RT (NCT07904182)
- Testing
- Absorbable Hydrogel Spacer
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Radiation Tolerance
Radiation Dosimetry in Teeth
Irradiation of any tissue creates changes in that tissue. Ionizing radiation imparts charges to the tissue as it interacts with tissue components, changing the tissue structure.
- Trial name
- NCT00178347
- Testing
- Exposure to irradiation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Rochester
Hypothyroidism, Thyroid Neoplasms
Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.
Thyroid cancer is typically treated with surgery, radiation or a combination of both. Following surgical removal of thyroid tissue patients receive thyroid hormone replacement medication.
- Trial name
- NCT00001730
- Testing
- Thyrogen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Neuroendocrine Tumors, Meningioma
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
- Trial name
- NCT03273712
- Testing
- 90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, Amino Acids
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Iowa
Lung Neoplasm, Pelvic Neoplasm
Personalized Estimation of Doses Delivered During Image Guided Radiation Therapy Tests
In image-guided radiotherapy (IGRT), the repeated and increasingly intensive use of on-board positioning imaging, using 2D or 3D Mega-Volt (MV) or kilo-Volt (kV) imaging devices (cone-beam or CBCT scanners), is leading the…
- Conditions
- Lung Neoplasm, Pelvic Neoplasm, Breast Cancer, Cancer, Otorhinolaryngeal
- Trial name
- ELISA (NCT05258383)
- Testing
- 3D maps of physical doses
- Where
- 9 sites in France
- Volunteers
- 320 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neuroendrocrine Tumors, Meningioma
Dosimetry Guided PRRT With 90Y-DOTATOC
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendrocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
- Trial name
- NCT03013387
- Testing
- 90Y-DOTA-3-tyr-Octreotide, Positron Emission Tomography (PET) whole body scan, Amino Acids
- Sponsor
- Sue O'Dorisio
Prostate Cancer (Adenocarcinoma)
LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.
A substantial proportion of patients with mCRPC do not respond to 177Lu-PSMA-RLT. The PSA response to Lu-PSMA was observed in nearly 46% of patients included in VISION trial and 66% in LuPSMA trial (4,5).
- Trial name
- LUDOPATH (NCT07370597)
- Where
- Belgium
- Volunteers
- 110 people
- Sponsor
- Jules Bordet Institute
Any Pathology Requiring a Cranial CT Imaging
Crystalline Exposition During Pediatric Cranial CT Imaging
This study focuses on reduction of X-rays dose applied to eye's lens during cranial CT in children. Principal objective is to analyse the efficiency of ocular bismuth masks, which are associated with an eye's lens dose modulation
- Trial name
- ECTOPIC (NCT03665181)
- Testing
- use or non-use of dose modulator and bismuth mask
- Where
- France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Bordeaux
Kawasaki Disease
A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects
The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.
- Trial name
- NCT00162045
- Testing
- Technetium Tc99m Sestamibi
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 79 people
- Sponsor
- Lantheus Medical Imaging
Neoplasm
Clinical Evaluation of a Laser Heated, Fiberoptic-Coupled Radiation Dose Verification System
We propose to determine the response of a newly developed laser heated, vycor glass fiberoptic radiation dosimetry system to ionizing radiation in a clinical radiotherapy environment.
- Trial name
- NCT00026871
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Adenoma, Liver Cell
Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry
The purpose of this study is to determine whether a treatment with Therasphere which is optimized is more efficient compared to a standard treatment for patients suffering from hepatocellular carcinomas.
- Trial name
- NCT02582034
- Testing
- Optimized Internal Radiation Therapy, Standard Internal Radiation Therapy
- Where
- 4 sites in France
- Volunteers
- 56 people
- Sponsor
- Center Eugene Marquis
Malignant Central Nervous System Neoplasm, Malignant Skull Base Neoplasm
Brain Imaging Changes Following Proton Therapy for Pediatric Primary Central Nervous System and Base of Skull Tumors
This trial gathers information from patients with primary central nervous system or base of skull tumors that receive proton beam therapy and see if certain imaging techniques can help detect radiation-related changes over time.
- Trial name
- NCT04296617
- Testing
- Medical Chart Review
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Neuroendocrine Tumors, Pheochromocytoma
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
This is a Phase I/II peptide receptor radiotherapy (PRRT) trial of 177Lu-DOTA-OCTREOTATE in children and adolescents with neuroendocrine tumors and pheochromocytoma or paraganglioma.
- Conditions
- Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NCT03923257
- Testing
- 177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT)
- Where
- United States
- Sponsor
- Sue O'Dorisio
Neuroblastoma, Neuroendocrine Tumor
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
This study is for patients with neuroblastoma or a neuroendocrine tumor who have not been able to have standard therapy or have failed the first-line therapy.
- Trial name
- NCT01048086
- Testing
- Retinoic Acid
- Where
- United States
- Sponsor
- University of Iowa